



(12) Translation of
European patent specification

(11) NO/EP 3026045 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 215/54 (2006.01)
A61K 31/4709 (2006.01)
A61K 31/5377 (2006.01)
A61P 9/00 (2006.01)
A61P 13/12 (2006.01)
A61P 25/02 (2006.01)
A61P 35/00 (2006.01)
A61P 35/02 (2006.01)
A61P 35/04 (2006.01)
A61P 37/02 (2006.01)
A61P 43/00 (2006.01)
C07D 401/12 (2006.01)
C07D 401/14 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2019.02.18
(80)	Date of The European Patent Office Publication of the Granted Patent	2018.10.03
(86)	European Application Nr.	14828976.2
(86)	European Filing Date	2014.07.23
(87)	The European Application's Publication Date	2016.06.01
(30)	Priority	2013.07.24, JP, 2013153350
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	ONO Pharmaceutical Co., Ltd., 1-5, Doshomachi 2-chome Chuo-ku, Osaka-shi, Osaka 541-8526, Japan
(72)	Inventor	INUKAI, Takayuki, c/o ONO PHARMACEUTICAL CO. LTD.1-1 Sakurai 3- chomeShimamoto-cho, Mishima-gunOsaka 618-8585, Japan TAKEUCHI, Jun, c/o ONO PHARMACEUTICAL CO. LTD.1-1 Sakurai 3- chomeShimamoto-cho, Mishima-gunOsaka 618-8585, Japan YASUHIRO, Tomoko, c/o ONO PHARMACEUTICAL CO. LTD.1-1 Sakurai 3- chomeShimamoto-cho, Mishima-gunOsaka 618-8585, Japan
(74)	Agent or Attorney	TANDBERG INNOVATION AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54)	Title	QUINOLINE DERIVATIVE
(56)	References Cited:	WO-A1-2006/116713, WO-A1-2012/011548, WO-A1-2009/137429, DATABASE REGISTRY

[Online] 16 January 2001 '3-QUINOLINECARBOXAMIDE, N-[5-[(7-CHLORO-4-QUINOLINYL)THIO]-1,3,4-THIADIAZOL-2-YL]-1,2-DIHYDRO-4-HYDROXY-2-OX O- (CA INDEX NAME)', XP055311240 Retrieved from STN Database accession no. 314026-41-0, WO-A1-2013/074633, WO-A2-2007/146824, WO-A1-2012/028332

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

EP3026045**Patentkrav**

- 5 **1.** Forbindelse valgt blant N-{5-[(6,7-dimetoksy-4-quinolinyloxy)-2-pyridinyloxy]-2,5-diookso-1-fenyl-1,2,5,6,7,8-heksahydro-3-quinolinkarboksamid og et salt deriv.
- 10 **2.** Forbindelsen ifølge krav 1, som er N-{5-[(6,7-dimetoksy-4-quinolinyloxy)-2-pyridinyloxy]-2,5-diookso-1-fenyl-1,2,5,6,7,8-heksahydro-3-quinolinkarboksamid.
- 15 **3.** Farmasøytisk sammensetning som inneholder forbindelsen ifølge krav 1.
- 20 **4.** Sammensetningen ifølge krav 1 for anvendelse i en fremgangsmåte for å forhindre og/eller behandle en Axl-relatert sykdom.
- 25 **5.** Forbindelsen for anvendelse ifølge krav 4, hvori den Axl-relaterte sykdommen inkluderer en kreft, en nyresykdom, en immunsystemsykdom eller en sykdom i sirkulasjonssystemet.
- 30 **6.** Forbindelsen for anvendelse ifølge krav 5, hvori kreften er akutt myeloid leukemi, kronisk myeloid leukemi, akutt lymfatisk leukemi, melanom, brystkreft, bukspyttkjertelkreft, gliom, adenokarsinom i spiserøret, tykktarmkreft, nyrecellekarsinom, skjoldbruskkreft, ikke-småcellet lungekreft, prostatakreft, magekreft, leverkreft, uvealt malignt melanom, eggstokkreft, livmorkreft, lymfom, hode- og
- 35 nalskreft eller sarkom.